Abstract 4362326: Impact of Early Reimplantation after Transvenous Lead Extraction of Infected Cardiac Implantable Electronic Device

Y Yuh Miin Sin (Aimst University, Bedong , Malaysia) M Min Choon Tan (Mayo Clinic Arizona, Phoenix, Arizona, United States) A Aravinthan Vignarajah (Cleveland Clinic Fairview Hospital, Fairview Park, Ohio, United States) R Ramzi Ibrahim (Mayo Clinic Arizona, Scottsdale, Arizona, United States) K Kamala Tamirisa (Texas Cardiac Arrhythmia Institute, Southlake, Texas, United States) A Andrea Russo D Dan Sorajja (Mayo Clinic Arizona, Phoenix, Arizona, United States) H Hicham El Masry (Mayo CLinic AZ, Phoenix, Arizona, United States)

Abstract

Background: Transvenous lead extraction (TLE) is the standard of care for cardiac implantable electronic device (CIED) infections. Data regarding the optimal timing of CIED reimplantation after TLE are not well established. Objective: This study aims to assess the 5-year outcomes of early (≤7 days) versus non-early (>7 days) CIED reimplantation following TLE for CIED infection using a multi-national database. Methods: Using the TriNetX Analytics Research Network, we included patients aged ≥18 years who underwent TLE for CIED infection between 1/1/2014 and 1/1/2020. Patients were further categorized into two groups: early CIED reimplantation (≤7 days from TLE) and non-early CIED reimplantation. Propensity score matching (PSM) was performed by including patient demographics, LVEF, cardiac comorbidities and medications. The study outcomes included all-cause mortality and cardiac adverse events during a 5-year study period. Results: A total of 1668 patients in the early CIED reimplantation group and 1550 in the non-early group were identified. After PSM, 1327 patients in each group were analyzed. Compared to non-early group, early CIED reimplantation group was associated with significantly higher odds of all-cause hospitalization (odds ratio [OR]: 1.837, 95% confidence interval [CI]: 1.532-2.203) and repeated device infection (OR: 1.569, 95% CI: 1.314-1.873) at 5-year follow-up. However, no significant differences were observed in all-cause mortality (OR: 0.927, 95% CI: 0.778-1.104), HF exacerbation (OR: 1.021, 95% CI: 0.855-1.218), cardiac arrest (OR:0.924, 95% CI: 0.739-1.157), stroke (OR: 1.169, 95% CI: 0.915-1.494), cardiac thrombus (OR: 1.163, 95% CI: 0.749-1.808), major bleeding (OR: 1.079, 95% CI: 0.857-1.358) and venous thromboembolism (OR: 0.923, 95% CI: 0.759-1.123) between the two groups. Conclusion: Early reimplantation of CIED following TLE of infected devices was associated with worse outcomes in all-cause hospitalization and repeated device infection. Further large prospective studies are needed to define the optimal timing of device reimplantation.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (8)

Y

Yuh Miin Sin

Aimst University, Bedong , Malaysia

M

Min Choon Tan

Mayo Clinic Arizona, Phoenix, Arizona, United States

A

Aravinthan Vignarajah

Cleveland Clinic Fairview Hospital, Fairview Park, Ohio, United States

R

Ramzi Ibrahim

Mayo Clinic Arizona, Scottsdale, Arizona, United States

K

Kamala Tamirisa

Texas Cardiac Arrhythmia Institute, Southlake, Texas, United States

A

Andrea Russo

D

Dan Sorajja

Mayo Clinic Arizona, Phoenix, Arizona, United States

H

Hicham El Masry

Mayo CLinic AZ, Phoenix, Arizona, United States